ABSTRACT
Monovalent, inactivated and adjuvanted vaccines against African horse sickness, prepared with serotypes 5 and 9, were tested on guinea-pigs to select the formulation that offered the greatest immunity. The final formulation of the vaccines took into account the immune response in the guinea-pig and the inflammatory properties of two types of adjuvant previously tested on target animals. A pilot study was subsequently conducted on horses using a vaccine prepared with serotype 9. The vaccine stimulated neutralising antibodies from the first administration and, after the booster dose, 28 days later; high antibody levels were recorded for at least 10 months. The guinea-pig appears to be a useful laboratory model for the evaluation of the antigenic properties of African horse sickness vaccines.
Subject(s)
African Horse Sickness Virus/immunology , African Horse Sickness/prevention & control , Viral Vaccines/immunology , Adjuvants, Immunologic , African Horse Sickness Virus/classification , Animals , Female , Guinea Pigs , Horse Diseases/prevention & control , Horses , Serotyping , Vaccines, Inactivated/immunologyABSTRACT
African horse sickness is a vector-transmitted viral disease that affects equidae. The authors report cases of disease that occurred in Namibia between 2006 and 2008. These were recorded by staff of the Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise 'G. Caporale' and the Central Veterinary Laboratory in Windhoek. All cases described were confirmed by laboratory testing. This study received the support of Namibian state and private veterinarians and horse breeders.
